{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:03:53Z","timestamp":1794128633495,"version":"4.8.0"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":632,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"DOI":"10.1093\/eurheartj\/ehv043","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T13:23:42Z","timestamp":1430486622000},"page":"1012-1022","source":"Crossref","is-referenced-by-count":1254,"title":["Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management"],"prefix":"10.1093","volume":"36","author":[{"given":"Erik S.","family":"Stroes","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[{"name":"University of Milan and Multimedica IRCSS Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgirene D.","family":"Vladutiu","sequence":"additional","affiliation":[{"name":"School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"St. Georges's University of London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, University Hospital D\u00fcsseldorf Heinrich-Heine University, and Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Stein","sequence":"additional","affiliation":[{"name":"Metabolic and Atherosclerosis Research Centre, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"Hacettepe University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[{"name":"Piti\u00e9-Salpetriere University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"De Backer","sequence":"additional","affiliation":[{"name":"Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Krauss","sequence":"additional","affiliation":[{"name":"Children's Hospital Oakland Research Institute, Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum des Saarlandes, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[{"name":"University of Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[{"name":"Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Academic Medical Center, University of Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Mach","sequence":"additional","affiliation":[{"name":"Cardiology Service, HUG, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[{"name":"Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie B.","family":"Newman","sequence":"additional","affiliation":[{"name":"New York University School of Medicine, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[{"name":"Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[{"name":"University of Milan and Multimedica IRCSS Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[{"name":"INSERM, Piti\u00e9-Salpetriere University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Columbia University, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"European Atherosclerosis Society Consensus Panel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgirene D.","family":"Vladutiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie B.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"John Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"John Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"de Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kees Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"key":"key\n\t\t\t\t20180328141709_EHV043C1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C3","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C4","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328141709_EHV043C5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C7","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C8","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328141709_EHV043C9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Int Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.22205","article-title":"Prevalence and risk factors of muscle complications secondary to statins","volume":"44","author":"El-Salem","year":"2011","journal-title":"Muscle Nerve"},{"key":"key\n\t\t\t\t20180328141709_EHV043C16","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328141709_EHV043C18","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328141709_EHV043C23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.eurheartj.a060485","article-title":"Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study","volume":"15","author":"Keech","year":"1994","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-9-6","article-title":"Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people","volume":"9","author":"MRC\/BHF Heart Protection Study Collaborative Group","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C27","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(14)70173-1","article-title":"Statin use before diabetes and risk of microvascular disease: a nationwide nested matched study","volume":"2","author":"Nielsen","year":"2014","journal-title":"Lancet Diabet Endocrinol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI Clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328141709_EHV043C29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0002-9149(01)01464-3","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin","volume":"87","author":"Downs","year":"2001","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C30","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1026132412074","article-title":"The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk","volume":"17","author":"Corsini","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C33","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(14)61765-7","article-title":"Misrepresentation of statin safety evidence","volume":"384","author":"Armitage","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C34","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180328141709_EHV043C38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C39","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1559-4572.2009.00055.x","article-title":"Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use","volume":"11","author":"Reddy","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key\n\t\t\t\t20180328141709_EHV043C40","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C41","article-title":"IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. A multicenter, double-blind, randomized study to establish the clinical benefit and safety of Vytorin (ezetimibe\/simvastatin tablet) vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome","author":"Cannon"},{"key":"key\n\t\t\t\t20180328141709_EHV043C42","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of Fluvastatin XL 80 mg alone, ezetimibe alone and the combination of Fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, double-blind, double-dummy trial","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C43","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-198019030-00001","article-title":"Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia","volume":"19","author":"Heel","year":"1980","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180328141709_EHV043C45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(87)90871-0","article-title":"Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia","volume":"83","author":"Knopp","year":"1987","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C46","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C47","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C48","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.amjcard.2012.06.050","article-title":"Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia","volume":"110","author":"Guo","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C49","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C50","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C51","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C52","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/ajcn\/71.6.1433","article-title":"Long term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia","volume":"71","author":"Anderson","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"key\n\t\t\t\t20180328141709_EHV043C53","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180328141709_EHV043C54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.2011.1202","article-title":"Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial","volume":"306","author":"Jenkins","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328141709_EHV043C55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180328141709_EHV043C56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of Coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clinic Proc"},{"key":"key\n\t\t\t\t20180328141709_EHV043C57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of Coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C58","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s001980200012","article-title":"Vitamin D and muscle function","volume":"13","author":"Pfeifer","year":"2012","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t20180328141709_EHV043C60","first-page":"111","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia \u2013 a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178C","author":"Michalska-Kasiczak","year":"2014","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejim.2014.06.008","article-title":"Nutraceuticals for the treatment of hypercholesterolemia","volume":"25","author":"Mannarino","year":"2014","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C62","doi-asserted-by":"crossref","first-page":"e98611","DOI":"10.1371\/journal.pone.0098611","article-title":"A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328141709_EHV043C63","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20180328141709_EHV043C64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-med-022613-090402","article-title":"Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9","volume":"65","author":"Stein","year":"2014","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C66","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C67","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328141709_EHV043C68","article-title":"ODYSSEY ALTERNATIVE: efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm","author":"Moriarty"},{"key":"key\n\t\t\t\t20180328141709_EHV043C69","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in 4 Phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328141709_EHV043C70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1586\/14779072.2014.954551","article-title":"Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction","volume":"12","author":"Tavori","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C71","article-title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t20180328141709_EHV043C72","article-title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t20180328141709_EHV043C73","article-title":"The Evaluation of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-1)","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t20180328141709_EHV043C74","article-title":"The Evaluation of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-2)","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t20180328141709_EHV043C75","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib","volume":"54","author":"Davidson","year":"2013","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20180328141709_EHV043C76","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328141709_EHV043C77","article-title":"REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t20180328141709_EHV043C78","article-title":"A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE)","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t20180328141709_EHV043C79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"key\n\t\t\t\t20180328141709_EHV043C80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C81","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20180328141709_EHV043C82","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C83","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2012.12.023","article-title":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","volume":"325","author":"Stringer","year":"2013","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180328141709_EHV043C85","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","article-title":"The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle","volume":"77","author":"Laaksonen","year":"1996","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C86","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"P\u00e4iv\u00e4","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C87","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.21847","article-title":"Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications","volume":"43","author":"Wu","year":"2011","journal-title":"Muscle Nerve"},{"key":"key\n\t\t\t\t20180328141709_EHV043C88","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C89","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180328141709_EHV043C90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C91","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1113\/jphysiol.2012.238022","article-title":"Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents","volume":"590","author":"Mallinson","year":"2012","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2011.10.044","article-title":"Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate","volume":"674","author":"Araki","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180328141709_EHV043C94","doi-asserted-by":"crossref","first-page":"e87495","DOI":"10.1371\/journal.pone.0087495","article-title":"Nitric oxide-dependent activation of CaMKII increases diastolic sarcoplasmic reticulum calcium release in cardiac myocytes in response to adrenergic stimulation","volume":"9","author":"Curran","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328141709_EHV043C95","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical functions of coenzyme Q10","volume":"20","author":"Crane","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"key\n\t\t\t\t20180328141709_EHV043C96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"key\n\t\t\t\t20180328141709_EHV043C97","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrendo.2011.138","article-title":"The role of mitochondria in insulin resistance and type 2 diabetes mellitus","volume":"8","author":"Szendroedi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C98","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1371\/journal.pmed.0040154","article-title":"Insulin-stimulated mitochondrial ATP synthesis occurs independently of intramyocellular lipid accumulation in well-controlled type 2 diabetic humans","volume":"4","author":"Szendroedi","year":"2007","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C99","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","article-title":"Simvastatin impairs exercise training adaptations","volume":"62","author":"Mikus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2131\/jts.36.445","article-title":"Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats","volume":"36","author":"Obayashi","year":"2011","journal-title":"J Toxicol Sci"},{"key":"key\n\t\t\t\t20180328141709_EHV043C101","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00498250802585539","article-title":"Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy","volume":"39","author":"Sidaway","year":"2009","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t20180328141709_EHV043C102","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.107.131615","article-title":"The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins","volume":"324","author":"Madsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180328141709_EHV043C103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbrc.2005.11.179","article-title":"Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats","volume":"340","author":"Naba","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20180328141709_EHV043C104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cmet.2014.05.003","article-title":"Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle","volume":"20","author":"Zhang","year":"2014","journal-title":"Cell Metab"},{"key":"key\n\t\t\t\t20180328141709_EHV043C105","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","author":"Limaye","year":"2014","journal-title":"Muscle Nerve"},{"key":"key\n\t\t\t\t20180328141709_EHV043C106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20180328141709_EHV043C107","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17425251003713519","article-title":"Efflux and uptake transporters as determinants of statin response","volume":"6","author":"Rodrigues","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C108","first-page":"877","article-title":"Drug therapy for hypercholesterolemia and dyslipidemia","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Bersot","year":"2011","edition":"12th ed"},{"key":"key\n\t\t\t\t20180328141709_EHV043C109","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2133\/dmpk.DMPK-12-RV-099","article-title":"Impact of genetic variation in OATP transporters to drug disposition and response","volume":"28","author":"Gong","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"key\n\t\t\t\t20180328141709_EHV043C111","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genome wide study","volume":"359","author":"SEARCH Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141709_EHV043C112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.07.001","article-title":"Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies","volume":"104","author":"Vladutiu","year":"2011","journal-title":"Molec Genet Metab"},{"key":"key\n\t\t\t\t20180328141709_EHV043C113","first-page":"264","article-title":"Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy","volume":"111","author":"Vladutiu","year":"2014","journal-title":"Molec Genet Metab"},{"key":"key\n\t\t\t\t20180328141709_EHV043C114","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1017\/S0317167100007630","article-title":"Metabolic myopathies discovered during investigations of statin myopathy","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"key\n\t\t\t\t20180328141709_EHV043C115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin-induced myalgia assessed by physiogenomic associations","volume":"218","author":"Rua\u00f1o","year":"2011","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180328141709_EHV043C116","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180328141709_EHV043C117","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13628","article-title":"GATM gene variants and statin myopathy risk","volume":"513","author":"Carr","year":"2014","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180328141709_EHV043C118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"key\n\t\t\t\t20180328141709_EHV043C119","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328141709_EHV043C120","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.107.185700","article-title":"ACC\/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery)","volume":"116","author":"Fleisher","year":"2007","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/36\/17\/1012\/17154081\/ehv043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T16:03:26Z","timestamp":1522253006000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/36\/17\/1012\/2465952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,18]]},"references-count":120,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2015,2,18]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehv043","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5,1]]},"published":{"date-parts":[[2015,2,18]]}}}